GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (FRA:DYF1) » Definitions » Cyclically Adjusted PB Ratio

Dynavax Technologies (FRA:DYF1) Cyclically Adjusted PB Ratio : 3.86 (As of Jun. 09, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies Cyclically Adjusted PB Ratio?

As of today (2024-06-09), Dynavax Technologies's current share price is €11.105. Dynavax Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €2.88. Dynavax Technologies's Cyclically Adjusted PB Ratio for today is 3.86.

The historical rank and industry rank for Dynavax Technologies's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:DYF1' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.62   Med: 2.5   Max: 5.38
Current: 3.82

During the past years, Dynavax Technologies's highest Cyclically Adjusted PB Ratio was 5.38. The lowest was 0.62. And the median was 2.50.

FRA:DYF1's Cyclically Adjusted PB Ratio is ranked worse than
74.66% of 742 companies
in the Drug Manufacturers industry
Industry Median: 1.875 vs FRA:DYF1: 3.82

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Dynavax Technologies's adjusted book value per share data for the three months ended in Mar. 2024 was €4.348. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.88 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Dynavax Technologies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Dynavax Technologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Cyclically Adjusted PB Ratio Chart

Dynavax Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.47 1.19 3.90 3.21 4.37

Dynavax Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.96 3.91 4.45 4.37 3.93

Competitive Comparison of Dynavax Technologies's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dynavax Technologies's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's Cyclically Adjusted PB Ratio falls into.



Dynavax Technologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Dynavax Technologies's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=11.105/2.88
=3.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dynavax Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Dynavax Technologies's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.348/131.7762*131.7762
=4.348

Current CPI (Mar. 2024) = 131.7762.

Dynavax Technologies Quarterly Data

Book Value per Share CPI Adj_Book
201406 4.218 100.560 5.527
201409 3.588 100.428 4.708
201412 3.098 99.070 4.121
201503 2.398 99.621 3.172
201506 2.196 100.684 2.874
201509 4.897 100.392 6.428
201512 4.467 99.792 5.899
201603 3.836 100.470 5.031
201606 3.208 101.688 4.157
201609 2.504 101.861 3.239
201612 2.191 101.863 2.834
201703 2.004 102.862 2.567
201706 2.284 103.349 2.912
201709 2.831 104.136 3.582
201712 2.740 104.011 3.471
201803 2.161 105.290 2.705
201806 1.795 106.317 2.225
201809 1.326 106.507 1.641
201812 0.882 105.998 1.096
201903 0.587 107.251 0.721
201906 0.144 108.070 0.176
201909 0.424 108.329 0.516
201912 0.089 108.420 0.108
202003 0.122 108.902 0.148
202006 0.473 108.767 0.573
202009 0.534 109.815 0.641
202012 0.438 109.897 0.525
202103 0.731 111.754 0.862
202106 0.603 114.631 0.693
202109 0.480 115.734 0.547
202112 1.601 117.630 1.794
202203 2.067 121.301 2.246
202206 3.163 125.017 3.334
202209 3.963 125.227 4.170
202212 4.298 125.222 4.523
202303 4.098 127.348 4.241
202306 4.137 128.729 4.235
202309 4.387 129.860 4.452
202312 4.404 129.419 4.484
202403 4.348 131.776 4.348

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dynavax Technologies  (FRA:DYF1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Dynavax Technologies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dynavax Technologies (FRA:DYF1) Business Description

Traded in Other Exchanges
Address
2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies (FRA:DYF1) Headlines

No Headlines